Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Shingrix Approved for Prevention of Shingles

GSK news release; 2017 Oct 23

The US Food and Drug Administration (FDA) has approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged ≥50 years.

Indications: Shingrix is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged ≥50 years. It is not indicated for prevention of primary varicella infection (chickenpox).

Dosage and administration: Administer 2 doses (0.5 mL each) at 0 and 2 to 6 months.

Adverse reactions: Solicited local adverse reactions in subjects aged ≥50 years were pain, redness, and swelling. Solicited general adverse reactions were myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.


Shingrix approved in the US for prevention of shingles in adults aged 50 and over. [news release]. London, UK: GlaxoSmithKline plc; October 23, 2017. Accessed October 24, 2017.